Athira Pharma Q2 net loss $29.6M ($0.78/sh); cash $196.3M; LIFT-AD results H2 2024

LeonaBio, Inc.

2023-Q2 EPS reported -$1.51

Net loss $29.6M ($0.78/sh) vs $24.3M ($0.65/sh) in Q2 2022; R&D spend rose to $21.6M.
Cash, cash equivalents and investments $196.3M at June 30, 2023, down from $245.2M at Dec 31, 2022.
Completed end-of-Phase 2 FDA meeting for fosgonimeton; LIFT-AD topline expected H2 2024.
Appointed Andrew Gengos as CFO and Chief Business Officer.
IND-enabling studies for ATH-1105 continue; first-in-human studies targeted H1 2024 for ALS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

LeonaBio, Inc. reported financial results for quarter ended June 30, 2023.

Period: quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041320

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.